Administration of certain drugs (for example, antiarrhythmics, antihistamines, antibiotics, antipsychotics) may occasionally affect myocardial repolarization and cause prolongation of the QT interval. We performed a whole genome association study of drug-induced QT prolongation after 14 days of treatment in a phase 3 clinical trial evaluating the efficacy, safety and tolerability of a novel atypical antipsychotic, iloperidone, in patients with schizophrenia. We identified DNA polymorphisms associated with QT prolongation in six loci, including the CERKL and SLCO3A1 genes. Each single nucleotide polymorphism (SNP) defined two genotype groups associated with a low mean QT change (ranging from À0.69 to 5.67 ms depending on the SNP) or a higher mean QT prolongation (ranging from 14.16 to 17.81 ms). The CERKL protein is thought to be part of the ceramide pathway, which regulates currents conducted by various potassium channels, including the hERG channel. It is well established that inhibition of the hERG channel can prolong the QT interval. SLCO3A1 is thought to play a role in the translocation of prostaglandins, which have known cardioprotective properties, including the prevention of torsades de pointes. Our findings also point to genes involved in myocardial infarction (PALLD), cardiac structure and function (BRUNOL4) and cardiac development (NRG3). Results of this pharmacogenomic study provide new insight into the clinical response to iloperidone, developed with the goal of directing therapy to those patients with the optimal benefit/risk ratio.
Introduction
QT prolongation is an electrographic repolarization abnormality of the cardiac muscle that can cause distinctive ventricular tachycardia (for example, torsades de pointes), and, in rare cases, sudden cardiac death. 1, 2 Many drugs, including antipsychotics, have the potential to prolong the QT interval 1, 3 by blocking the rapidly activating delayed rectifier current (I Kr ). 4 Recent evidence suggests that only 5-15% of persons who experience drug-induced torsades de pointes carry a mutation in one of the ion channel genes associated with hereditary long QT syndrome (LQTS). 2, 5 It is likely that other genes and environmental factors contribute to drug-induced LQTS. Although there is a poor correlation between the extent of QT prolongation and the occurrence of torsades de pointes, 6 identifying new genetic factors that predispose patients to drug-induced QT prolongation may help in understanding and in preventing this type of ventricular tachycardia.
Iloperidone is a novel antipsychotic that, like other typical and atypical antipsychotics, has been observed to have some effects on QT interval duration. Importantly, no evidence to date indicates that any patient treated with iloperidone has experienced torsades de pointes. To identify new genetic markers of drug-induced QT prolongation, we conducted a whole genome association study (WGAS) in a phase 3 trial of iloperidone. This clinical trial was a randomized, double-blind, placebo-controlled and ziprasidone-controlled multicenter study evaluating the efficacy, safety and tolerability of a 24 mg per day dose of iloperidone administered twice a day (b.i.d.) for 28 days to patients with schizophrenia in acute exacerbation. 7 
Methods
Ethical conduct of the study This clinical study was conducted in accordance with the Declaration of Helsinki. QT interval. Twelve-lead electrocardiography (ECG) was performed at baseline and on days 7, 14, 21 and 28. Except at baseline, ECG was performed 2 h after patients had received the morning dose of study drug. ECG was performed three times at baseline and on day 14, with single measurements obtained for other visits. QTc interval was calculated based on Fridericia correction (QTcF). The effect of iloperidone on QTc interval was measured by the mean change from baseline in QTc.
Patients and study design
Genotyping. We genotyped DNA samples for more than 500 000 single nucleotide polymorphisms (SNPs) with the use of an array set according to the manufacturer's instructions (GeneChip Human Mapping 500K Array Set; Affymetrix, Santa Clara, CA, USA). The set was composed of two arrays, each capable of genotyping on average 250 000 SNPs (approximately 262 000 for Nsp arrays and 238 000 for Sty arrays). To ensure the integrity of the data collected from DNA arrays, the following quality control steps were taken.
Algorithms. Each microarray (GeneChip Human 500K Array Set; Affymetrix) was analyzed with the dynamic model-based genotyping algorithm 8 and with the latest Bayesian robust linear model with Mahalanobis distance classifier (BRLMM); the confidence threshold was 0.5. 9 Under these conditions, missing genotypes were assumed missing at random, and no imputation was made for any genetic data. The BRLMM Analysis Tool 2.0 and the SNP Signal Tool 1.0.0.12 (Affymetrix) were used to analyze and visualize the distribution and separation of genotype calls of individual SNPs.
Call rate. Call rate was defined for a single array as the percentage of SNPs that were called A/A, A/B or B/B by the BRLMM algorithm. Only arrays with X93% call rate were retained for further analyses.
Concordance between arrays. Of the more than 500 000 SNPs genotyped, 50 were common to both Sty and Nsp arrays. Only arrays with greater than 90% concordance for these SNPs were used in further analyses.
Uniqueness of samples. The approximately 250 000 SNP data obtained per sample on each array (Sty or Nsp) were compared with the genotypes of all other samples to identify potential duplicate samples. If more than 90% of the genotypes were identical between the two arrays, DNA was retested to confirm genotypes and, if necessary, to eliminate duplicate samples.
Lack of DNA contamination. Lack of DNA contamination of a sample by another sample was assessed for each array by determining the overall percentage of SNPs with heterozygote calls, as calculated by the dynamic model algorithm. Genotype calls from arrays with < 30% heterozygote calls were considered to have come from a pure DNA sample. Only arrays with < 30% heterozygote calls were used for further analyses.
Sex determination. For each DNA sample, sex was blindly determined by the BRLMM algorithm based on the percentage of heterozygosity of the SNPs on the X chromosome. The result was compared with the expected sex. In case of divergent data, a polymerase chain reaction (PCR)-based assay for the amelogenin gene (AMELX) was performed on the original sample and on a new DNA aliquot. A new genotyping experiment was performed with the Sty and Nsp arrays. Samples with incompatible results were excluded from the WGAS.
Allele frequency. This project focused on the most common polymorphisms by selection of SNPs that had a minor allele frequency of 10% or more.
SNP selection. A reference DNA (Human Genomic DNA 103 control; Affymetrix) with available genotypes for SNPs on the array set (GeneChip Human 500K Array Set; Affymetrix) was systematically tested in parallel with the patients' samples. Eight DNA 103 replicates for both the Sty and Nsp arrays were obtained and analyzed. Individual SNP assays were considered accurate when genotype calls were identical across the eight replicates and the reference provided by Affymetrix. Only SNPs with 100% concordance for DNA 103 were retained for the WGAS. Five SNPs that cross-hybridized with the Y chromosome and all SNPs on the X chromosome were not used. Total number of SNPs analyzed in this WGAS was 339 272.
DNA sequencing. For each SNP of interest, a minimum of 15 DNA samples-including at least 5 samples for each homozygote and heterozygote genotype-were sequenced. The following primers were used for standard PCR amplification before sequencing: 0 -GTAGGAGGGAGGGCAAGAAC-3 0 (forward) and 5 0 -CAATCCGGTGCCAGAGTC-3 0 (reverse) for rs3924426. Sequencing was performed with a reagent kit (GeneAmp PCR Reagent Kit with AmpliTaq DNA Polymerase; Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions for a 25-ml reaction. Nucleotide sequences were determined using an automated capillary DNA sequencer (Avant 3100; Applied Biosystems) and a cycle sequencing kit (BigDye Terminator version 3.1 Cycle Sequencing Kit; Applied Biosystems) according to the manufacturer's instructions.
Statistical analysis
Genetic markers associated with prolongation of QTcF were identified through general linear model (GLM) analysis. The dependent variable was mean change from baseline to day 14 because the effects on QT were greatest by day 14, when iloperidone achieves steady state concentration. Baseline QTcF was used as a covariate, and genotype was used as the classifiable variable. The GLM used type 3 sums of squares, with all pairwise differences produced among the least squares means. As three genetic models (A/A vs non-A/A; A/B vs non-A/B; B/B vs non-B/B) were tested for each of the 334 563 SNPs, a total of 1 003 689 tests were performed. The Benjamini and Hochberg 10 procedure was used to control for the expected proportion of false discovery rate (FDR). FDR corrections were obtained from PROC MULT-TEST (SAS Institute, Cary, NC, USA), which produces Benjamini and Hochberg adjustments to original analytical P-values. Significance thresholds of 0.1 and 0.25 have been used in the analysis of quantitative traits in case of large multiplicity problems. 11, 12 More recently, Benjamini and Yekutieli 13 recommended not going higher than 0.2. Given that we performed more than 1 million tests, we set our BH-adjusted threshold at P < 0.2. For each SNP identified as a candidate biomarker of iloperidone response, post-hoc analyses were conducted to investigate the effects of sex and race. A posthoc permutation test was performed with 100 000 random samples for each of the selected SNPs. The following methodology was used for the random permutation test performed with each SNP: for each iteration, the class labels, that is, the genotype, were randomly shuffled using the SAS RANUNI function (SAS Institute) across the individuals. A GLM was performed on each random sample as described above. The observed P-values were then compared to the distribution of permuted P-values to obtain insight into the power of this method for each of the SNPs.
Linkage disequilibrium analysis
Pairwise linkage disequilibrium (LD) analysis was performed with Haploview v4.0 14 using genotype data of the iloperidone-treated patients. The D 015 and the log of the likelihood odds ratio (LOD), a measure of confidence in the value of D 0 , were examined.
Results
The effect of iloperidone on the QT interval was shown to be greatest by day 14, when iloperidone achieves steady state concentrations. Therefore, we calculated the change in QT interval between baseline and day 14. The Fridericia correction (QTcF) was applied, and a GLM statistical analysis using baseline as a covariate was performed. Of the 339 272 SNPs analyzed, 23 SNPs from 18 distinct chromosome regions had a BH-adjusted P < 0.2 after FDR correction, all with raw P < 0.000005. We focused our analysis on those SNPs located within or close to genes (< 10 kb away) in which the minor genotype group included at least 10% of the patients. Six SNPs of interest were identified in the CERKL, SLCO3A1, BRUNOL4, NRG3, NUBPL and PALLD genes ( Table 1) . Sensitivity analysis that was performed for each of these six SNPs verified that the underlying genotype distributions did not artificially increase the likelihood of positive association. In five of the six SNPs, the observed raw P-value was more significant than all 100 000 P-values generated by the randomization test. The observed raw P-value of the sixth SNP (rs7142881, NUBPL) fell within the 0.00003 tail of the empirical distribution of raw P-values.
The possibility that changes in the QT interval reflect drug concentration differences could not be excluded because drug exposure at the time of ECG was not known. However, the six SNPs identified here are within genes not expected to play a role in drug absorption, metabolism or excretion. For these SNPs, genotype calls generated by the microarray set were confirmed by sequencing on a random subset of DNA samples of iloperidone-treated patients. The association of a particular genotype class with lower or higher increased QT was consistent between men and women (data not shown) and across races ( Table 2 ). Additional SNPs with statistical association at P < 0.001 were observed within or near the CERKL, SLCO3A1, BRUNOL4, NRG3, NUBPL and PALLD genes (Figure 1) . SNP rs993648 is located within intron 2 of the CERKL gene (Figure 1a) , which codes for a ceramide kinase-like protein. Patients treated with iloperidone who were heterozygous for rs993648 had, at day 14, a mean QTcF change of 4.5 ms compared with 17.8 ms for homozygous patients (P = 2.83 Â 10 -6
; Table 1 ). The CERKL protein has sequence similarity with a ceramide kinase coded by another gene, CERK, and with sphingosine kinases 1 and 2. 16 Ceramide kinases convert the sphingolipid ceramide to ceramide-1-phosphate. Several studies have demonstrated that ceramide regulates transmembrane currents conducted by various potassium channels, including hERG. The hERG channel underlies the rapid component of the delayed rectifier current (I Kr ), which contributes to the repolarization of the cardiac action potential. It has been shown that ceramide downregulates the surface expression of the hERG protein and evokes a decrease in the hERG current. 18 The action of ceramide on ion channels is thought to be mediated mainly by kinase activity. 19, 20 Little is known about the function of the CERKL protein, and in-vitro experiments have failed to demonstrate that CERKL can actually phosphorylate ceramides. 16 The binding affinity of the CERKL protein for ceramide and ceramide derivatives, and the identity of cofactors that may play a role in its in-vivo activities remain to be explored. It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype. Several CERKL isoforms have been described, 16, 21, 22 but it is unknown whether they are associated with specific allelic variants and whether they interact as heterodimers. Our results suggest that studying the involvement of CERKL and, more broadly, the ceramide pathway may lead to better understanding of the mechanism of QT prolongation induced by antipsychotic medications or other drugs known to affect the QT interval. SNP rs3924426 is located within intron 1 of the SLCO3A1 gene (Figure 1b) . SLCO3A1 encodes the solute carrier organic anion transporter family, member 3A1, known as organic anion transporting polypeptide, subtype D (OATP-D). Patients who carried the rs3924426 non-T/T genotype had, at day 14, a mean QTcF change of 2.5 ms compared with 15.0 ms for the homozygous T/T patients. OATP-D is predominantly expressed in the brain, testis and heart, particularly in the myocardium, vascular P-values from the GLM analysis are provided before (Raw) and after FDR correction (BH-adjusted P-values). The lowest P-value of the permutation test performed with 100 000 random samples for each SNP is shown (P permutation). a Genotypes correspond to the þ strand of the DNA as reported at NCBI dbSNP. b Genotype classes associated with the lowest mean increased QT. c Genotype classes associated with the highest mean increased QT. endothelium and coronary artery. 23 In addition, OATP-D plays an important role in translocating prostaglandins E1, E2 and F2a in specialized cells and tissues. 23 It has been shown that prostaglandins have cardioprotective effects 24 and that, in particular, prostaglandin E2 can prevent torsades de pointes in rabbits treated with the antiarrhythmic drug clofilium. 6 Our results provide the first evidence of a possible direct link between SLCO3A1 and myocardial repolarization. SNP rs4799915 is located within intron 2 of the BRUNOL4 gene (Figure 1c) , which codes for the RNAbinding protein bruno-like 4. Patients who carried the rs4799915 C/C genotype had, at day 14, a mean QTcF change of 2.9 ms compared with 14.5 ms for patients with a different genotype ( Table 1 ). The BRUNOL4 gene product, CELF4, belongs to a family of RNAbinding proteins (BRUNOL or CELF proteins) that regulate pre-mRNA alternative splicing and that may be involved in mRNA editing and translation. 25 The BRUNOL2 and BRUNOL3 proteins are highly expressed in the heart, [25] [26] [27] and it has been suggested that they play a role in the pathogenesis of various skeletal muscle and heart diseases. 28, 29 Transgenic mice with a nuclear dominant-negative CELF4 protein, which was expressed specifically in the heart, exhibited defects in the alternative splicing of premRNA and developed cardiac hypertrophy, dilated cardiomyopathy, severe cardiac dysfunction and premature death. 27 This phenotype was rescued by increased cardiac expression of a wild-type CELF protein. 27 CELF proteins may play a key role in the regulation of alternative splicing crucial in the maintenance of normal cardiac structure and function. 27, 30 It would be of interest to further investigate how this protein family may be involved in myocardial repolarization, particularly CELF4, which was associated in our study with drug-induced QT prolongation. SNP rs4933824 is located within intron 1 of the neuregulin 3 (NRG3) gene (Figure 1d) . Patients who carried the rs4933824 non-G/G genotype had, at day 14, a mean QTcF change of 4.4 ms compared with 15.3 ms for patients with a different genotype ( Table 1) . Neuregulins are growth and differentiation factors related to epidermal growth factor, and they are ligands for receptor tyrosine kinases of the ErbB family. NRG3 was shown to be expressed in the developing human central nervous system, with a role in oligodendrocyte survival. 31 More recently it was also demonstrated that NRG3 is involved in mammary gland development 32 and is expressed in breast tumors. 33 Another neuregulin gene, NRG1, which is expressed in coronary microvascular endothelial cells, can promote the proliferation of embryonic cardiac myocytes and the growth and survival of ventricular myocytes in vitro. 34 This led to the suggestion that the neuregulin-ErbB signaling system plays an important role in the onset of myocardial trabeculation and cardiac morphogenesis. 34 What role neuregulin 3 plays in cardiac function, particularly in myocardial repolarization, remains to be explored. SNP rs7142881 is located within intron 4 of the nucleotide-binding protein-like (NUBPL) gene (Figure 1e) . Patients who carried the rs7142881 G/G genotype had, at day 14, a mean QTcF change of 5.7 ms compared with 16.7 ms for patients with a 17 and are listed in ascending order of dbSNP number. The gene name corresponds to the NCBI official symbol. Number of patients (N) and mean change in QT (in ms; Mean) are shown per race. a Genotypes correspond to the þ strand of the DNA as reported at NCBI dbSNP. b Genotype classes associated with the lowest mean increased QT. c Genotype classes associated with the highest mean increased QT. different genotype (Table 1) . At this time, the site(s) of expression of the NUBPL gene and the function of the encoded protein are unknown.
SNP rs17054392 is located within intron 2 of the paladin (PALLD) gene (Figure 1f) , which codes for the cytoskeletal-associated protein paladin, a component of actin-containing microfilaments that control cell shape, adhesion and contraction. Patients who were heterozygous for rs17054392 had a mean QTcF change of À0.7 ms compared with 14.2 ms for patients with a different genotype ( Table 1) . Other SNPs located in introns 2, 8 and 10 of PALLD also were significant at P < 0.01. Previously, another polymorphism within intron 10 (rs12510359, not tested in our WGAS) had been associated with risk for myocardial infarction. 35 The paladin protein is thought to play a critical role in cytoskeletal remodeling and to be able to respond to signals induced by vascular injury and signals that induce smooth muscle cell hypertrophy. 36 Our results suggest that PALLD may also affect myocardial repolarization.
Pairwise LD analysis revealed that SNPs associated with QTcF change with P < 0.001 in the CERKL, BRUNOL4 and NUBPL genes, were strongly linked. Pairwise LD analysis between rs993648 and rs993650 (CERKL) revealed a LOD of 51.3 and 77.5 in the Caucasian and African-American populations, respectively, both with D 0 = 1. For rs4799915 (BRUNOL4), D 0 was > 0.98 and LOD was > 50 in both papulations. For rs7142881 (NUBPL), pairwise analyses showed LOD ranging from 1.8 to 45.5 and from 18.2 to 65.7 in the Caucasian and African-American populations, respectively, with all D 0 > 0.9. In contrast, the absence of significant LD between SNPs in the SLCO3A1, NRG3 and PALLD regions (no D 0 with LOD > 0.6 in both Caucasian and African-American patients) suggests potential independent associations for these SNPs.
Discussion
Previous genetic research of QT prolongation has focused mainly on ion channel genes, but new genome-wide approaches provide the opportunity to identify genetic variants in unsuspected genes. Recently, a polymorphism that modulates cardiac repolarization was identified in a regulator of neuronal nitric oxide synthase. 37 In this first WGAS of druginduced QT prolongation, we have identified several genetic polymorphisms associated with prolongation of the QT interval in patients with schizophrenia treated with iloperidone. These polymorphisms point to genes with a known or suspected myocardial role but not previously associated with cardiac repolarization or ventricular tachycardia. These results suggest the possible interplay of genes involved in the ceramide pathway (CERKL), prostaglandin transport (SLCO3A1), cardiac structure and function (BRU-NOL4), cardiac development (NRG3) and myocardial infarction (PALLD), and of other genes such as NUBPL. It is possible that other genetic models, not tested in our analyses, including the additive and multiplicative models, could have suggested additional potential candidates.
It is also important to note that, while patients with serious cardiovascular conditions and clinically relevant ECG abnormalities were excluded from the trial, it is not impossible that undetected medical conditions unrelated to the drug treatment may also have contributed to QT prolongation in some of the patients. Other potential confounding factors such as the previous exposure to other antipsychotics and/or concomitant medications not analyzed here could have played a role in changes of the QT interval. Although validation of these findings may necessitate another well-powered clinical trial, these results offer new hypotheses of the genetic predisposition to druginduced QT prolongation and indicate new candidate genes for hereditary LQTS. Analysis of these genetic markers with QT prolongation induced by various drugs, particularly other antipsychotics, will determine whether they are specific to iloperidone or associated with particular classes of drugs. Results of these pharmacogenomic studies should provide physicians a new tool for evaluating the benefit/risk ratio of the drug and for making better-informed decisions about the optimal treatment for each patient.
